Reported about 9 hours ago
Eli Lilly shares fell over 6% after the company revised its revenue guidance for Q4 2024, predicting $13.5 billion, which was below Wall Street's expectations of $14 billion. This downgrade was attributed to slower-than-expected growth in weight-loss drug sales and lower year-end channel inventory, despite a 45% increase from the same quarter in 2023. Analysts remain optimistic about future performance and pipeline developments.
Source: YAHOO